Study Title

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer

Study Details

Description:

This clinical trial will evaluate the safety of Radium-223 in combination with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Phase I/II study

Sponsor:

Peter MacCallum Cancer Centre

Contacts:

Gaurav Sharma

gaurav.sharma@petermac.org

03 85596830

Dr Louise Kostos, MBBS, FRACP

louise.kostos@petermac.org

Prof Michael Hofman (Principal Investigator)

Government Study Link:

NCT05383079 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468